Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Amicus Therapeutics, Inc. is a publicly traded biotechnology company focused on the discovery, development, and commercialization of medicines for people living with rare and orphan diseases. The company operates within the biopharmaceutical and rare disease therapeutics industries, with a strategic emphasis on genetically defined conditions that have high unmet medical need. Its commercial portfolio is centered on treatments for Fabry disease and Pompe disease, which represent its primary revenue drivers.
The company’s lead marketed products include Galafold (migalastat) for Fabry disease and the combination therapy Pombiliti (cipaglucosidase alfa) with Opfolda (miglustat) for late-onset Pompe disease. Amicus is positioned as a differentiated rare-disease company through its focus on precision medicine, oral and biologic therapies, and long-term engagement with patient communities. Founded in 2002, Amicus evolved from a research-stage biotechnology firm into a fully integrated commercial organization following regulatory approvals in the U.S., Europe, and other international markets.
Business Operations
Amicus operates as a single-reportable segment biotechnology company, generating revenue primarily from global product sales of Galafold and Pombiliti/Opfolda. Commercial operations span patient identification, regulatory engagement, manufacturing oversight, and specialty distribution, with increasing emphasis on lifecycle management and label expansion for its approved therapies.
The company maintains internal capabilities across research and development, clinical operations, regulatory affairs, and global commercial infrastructure. Amicus controls proprietary protein engineering and pharmacological chaperone technologies that underpin its product portfolio. Its operations are supported by wholly owned subsidiaries including Amicus Therapeutics UK Ltd. and other international entities that facilitate regional commercialization and regulatory activities. Manufacturing is conducted through a combination of internal oversight and third-party contract manufacturing organizations.
Strategic Position & Investments
Strategically, Amicus is focused on maximizing the global potential of its Fabry and Pompe disease franchises while advancing follow-on innovations that improve clinical outcomes and patient convenience. Growth initiatives include geographic expansion of approved products, increased market penetration through earlier diagnosis, and post-approval studies to support long-term adoption.
The company has made significant investments in the development and regulatory approval of Pombiliti/Opfolda, representing a major expansion beyond Fabry disease into Pompe disease. While Amicus has previously explored gene therapy and next-generation biologics, some programs have been discontinued as part of portfolio prioritization. The company’s current strategy emphasizes disciplined capital allocation, execution in rare disease markets, and sustainable commercial growth rather than broad-based pipeline diversification.
Geographic Footprint
Amicus Therapeutics is headquartered in Cranbury, New Jersey, with a global operational footprint spanning North America, Europe, and parts of Asia-Pacific. The company has established direct commercial presence in key markets including the United States, Germany, United Kingdom, Italy, Spain, and Japan, with additional reach through distributors in other regions.
Its therapies are approved and reimbursed across multiple international jurisdictions, giving Amicus meaningful influence in global rare disease markets. International operations are integral to revenue generation, as a substantial portion of patients treated with Galafold and Pombiliti/Opfolda reside outside the United States.
Leadership & Governance
Amicus was founded by John F. Crowley, whose personal connection to rare disease shaped the company’s mission-driven culture and long-term strategy. Leadership emphasizes patient-centric development, scientific rigor, and disciplined execution in highly specialized markets. Governance is structured to support regulatory compliance, shareholder accountability, and sustainable growth.
Key members of the executive leadership team include:
- Bradley L. Campbell – President & Chief Executive Officer
- John F. Crowley – Chairman of the Board
- James Iacocca – Chief Financial Officer
- Jesse L. Goodman, MD, MPH – Chief Medical Officer